Ceritinib and alectinib are second-generation ALK inhibitors with improved potency and selectivity against the kinase activities of ALK. Due to its proven superior efficacy and lower toxicity, Alectinib is now approved as first-line treatment for ALK NSCLC and in patients prescribed crizotinib in whom disease progression has occurred. This evidence concerns the gene ALK and non-small cell lung carcinoma.